JP2019515052A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515052A5 JP2019515052A5 JP2019512184A JP2019512184A JP2019515052A5 JP 2019515052 A5 JP2019515052 A5 JP 2019515052A5 JP 2019512184 A JP2019512184 A JP 2019512184A JP 2019512184 A JP2019512184 A JP 2019512184A JP 2019515052 A5 JP2019515052 A5 JP 2019515052A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- alkyl
- anticholinesterase
- composition according
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 13
- 210000003205 muscle Anatomy 0.000 claims description 7
- 108030001720 Bontoxilysin Proteins 0.000 claims description 5
- 229940053031 botulinum toxin Drugs 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 101710138657 Neurotoxin Proteins 0.000 claims description 3
- 239000002581 neurotoxin Substances 0.000 claims description 3
- 231100000618 neurotoxin Toxicity 0.000 claims description 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 claims 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 229960002290 pyridostigmine Drugs 0.000 claims 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- VWLHWLSRQJQWRG-UHFFFAOYSA-O Edrophonum Chemical compound CC[N+](C)(C)C1=CC=CC(O)=C1 VWLHWLSRQJQWRG-UHFFFAOYSA-O 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000010428 Muscle Weakness Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 claims 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 229960003748 edrophonium Drugs 0.000 claims 1
- 229960003980 galantamine Drugs 0.000 claims 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960002362 neostigmine Drugs 0.000 claims 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 229960001697 physostigmine Drugs 0.000 claims 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000001453 quaternary ammonium group Chemical group 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 229960004136 rivastigmine Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000005062 synaptic transmission Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 230000005540 biological transmission Effects 0.000 description 3
- 230000002232 neuromuscular Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022063952A JP2022088660A (ja) | 2016-05-13 | 2022-04-07 | 化学的除神経から生じる副作用の処置 |
| JP2024067205A JP2024099644A (ja) | 2016-05-13 | 2024-04-18 | 化学的除神経から生じる副作用の処置 |
| JP2025064212A JP2025108527A (ja) | 2016-05-13 | 2025-04-09 | 化学的除神経から生じる副作用の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662336344P | 2016-05-13 | 2016-05-13 | |
| US62/336,344 | 2016-05-13 | ||
| PCT/US2017/032636 WO2017197382A1 (en) | 2016-05-13 | 2017-05-15 | Treating of side-effects resulting from chemodenervation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022063952A Division JP2022088660A (ja) | 2016-05-13 | 2022-04-07 | 化学的除神経から生じる副作用の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019515052A JP2019515052A (ja) | 2019-06-06 |
| JP2019515052A5 true JP2019515052A5 (https=) | 2020-06-25 |
Family
ID=60266879
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019512184A Pending JP2019515052A (ja) | 2016-05-13 | 2017-05-15 | 化学的除神経から生じる副作用の処置 |
| JP2022063952A Pending JP2022088660A (ja) | 2016-05-13 | 2022-04-07 | 化学的除神経から生じる副作用の処置 |
| JP2024067205A Pending JP2024099644A (ja) | 2016-05-13 | 2024-04-18 | 化学的除神経から生じる副作用の処置 |
| JP2025064212A Pending JP2025108527A (ja) | 2016-05-13 | 2025-04-09 | 化学的除神経から生じる副作用の処置 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022063952A Pending JP2022088660A (ja) | 2016-05-13 | 2022-04-07 | 化学的除神経から生じる副作用の処置 |
| JP2024067205A Pending JP2024099644A (ja) | 2016-05-13 | 2024-04-18 | 化学的除神経から生じる副作用の処置 |
| JP2025064212A Pending JP2025108527A (ja) | 2016-05-13 | 2025-04-09 | 化学的除神経から生じる副作用の処置 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11129822B2 (https=) |
| EP (1) | EP3454855B1 (https=) |
| JP (4) | JP2019515052A (https=) |
| KR (2) | KR20190008225A (https=) |
| CN (2) | CN109414434A (https=) |
| AU (2) | AU2017263850A1 (https=) |
| BR (1) | BR112018073388A2 (https=) |
| CA (1) | CA3023408A1 (https=) |
| IL (1) | IL262916A (https=) |
| WO (1) | WO2017197382A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3709993A4 (en) * | 2017-11-15 | 2021-08-04 | Delnova, Inc. | TREATMENT OF SIDE EFFECTS OF BOTULINUM THERAPIES |
| WO2025226839A2 (en) * | 2024-04-23 | 2025-10-30 | New York University | Auf1 compositions and methods for promoting generation of neuromuscular junctions |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4925856A (en) * | 1987-07-28 | 1990-05-15 | Sri International | Aldoxime-substituted imidazolium derivatives useful in the treatment of poisoning by phosphorus-containing chemicals |
| US6165500A (en) * | 1990-08-24 | 2000-12-26 | Idea Ag | Preparation for the application of agents in mini-droplets |
| EP0619814A1 (en) * | 1991-12-31 | 1994-10-19 | Fujisawa Pharmaceutical Co., Ltd. | Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity |
| GB9410871D0 (en) * | 1994-05-31 | 1994-07-20 | Imperial College | Modification of tetanus toxin for use as a transport protein |
| US7138127B1 (en) * | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
| US6759552B2 (en) * | 2002-03-28 | 2004-07-06 | Council Of Scientific And Industrial Research | Compound as cholinesterase inhibitor and its isolation from fungus sporotrichum species |
| CN1260349C (zh) * | 2003-04-29 | 2006-06-21 | 云南省微生物研究所 | 南宁链霉菌 |
| GB0518443D0 (en) * | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| US20080090808A1 (en) * | 2006-10-17 | 2008-04-17 | Franklin Volvovitz | Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction |
| CA2699412A1 (en) * | 2007-09-12 | 2009-03-19 | Virginia Tech Intellectual Properties, Inc. | Insecticidal carbamates exhibiting species-selective inhibition of acetylcholinesterase (ache) |
| CN101386818B (zh) * | 2008-07-29 | 2011-01-19 | 中山大学 | 一种海洋真菌培养物的提取物及其制备方法和应用 |
| WO2011009626A1 (en) * | 2009-07-24 | 2011-01-27 | Lipotec, S.A. | Compounds which inhibit muscle contraction |
| KR101067153B1 (ko) * | 2009-10-16 | 2011-09-22 | 경상대학교산학협력단 | 뇌신경 세포 보호 활성 및 아세틸콜린에스테라제 저해 활성을 갖는 율피 추출물 및 그의 용도 |
| WO2011075623A1 (en) | 2009-12-18 | 2011-06-23 | Latitude Pharmaceuticals, Inc. | One - phase gel compos ition compri s ing phos pholi pids |
| JP2014520148A (ja) * | 2011-06-20 | 2014-08-21 | セントルイス ユニバーシティ | 治療のための神経筋接合部への標的化 |
| CN103524515B (zh) * | 2012-07-03 | 2016-07-06 | 浙江海正药业股份有限公司 | 具有乙酰胆碱酯酶抑制活性的苯并间二氧杂环戊烯衍生物及其制备方法和用途 |
| CA2884566A1 (en) * | 2012-09-10 | 2014-03-13 | Matthew R. Lewin | Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade |
| EP4088724B1 (en) * | 2014-06-19 | 2024-10-23 | Attillaps Holdings | Acetylcholinesterase inhibitors for the oral treatment of dermatological conditions |
-
2017
- 2017-05-15 US US16/099,581 patent/US11129822B2/en active Active
- 2017-05-15 EP EP17797017.5A patent/EP3454855B1/en active Active
- 2017-05-15 WO PCT/US2017/032636 patent/WO2017197382A1/en not_active Ceased
- 2017-05-15 CN CN201780041576.4A patent/CN109414434A/zh active Pending
- 2017-05-15 BR BR112018073388A patent/BR112018073388A2/pt not_active Application Discontinuation
- 2017-05-15 KR KR1020187032859A patent/KR20190008225A/ko not_active Ceased
- 2017-05-15 JP JP2019512184A patent/JP2019515052A/ja active Pending
- 2017-05-15 CN CN202510057014.5A patent/CN119950719A/zh active Pending
- 2017-05-15 AU AU2017263850A patent/AU2017263850A1/en not_active Abandoned
- 2017-05-15 KR KR1020227011091A patent/KR20220063197A/ko not_active Ceased
- 2017-05-15 CA CA3023408A patent/CA3023408A1/en active Pending
-
2018
- 2018-11-11 IL IL262916A patent/IL262916A/en unknown
-
2021
- 2021-09-15 US US17/475,576 patent/US20220175753A1/en not_active Abandoned
-
2022
- 2022-04-07 JP JP2022063952A patent/JP2022088660A/ja active Pending
-
2023
- 2023-03-24 AU AU2023201832A patent/AU2023201832A1/en not_active Abandoned
-
2024
- 2024-04-18 JP JP2024067205A patent/JP2024099644A/ja active Pending
-
2025
- 2025-04-09 JP JP2025064212A patent/JP2025108527A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK168514B1 (da) | Synergistisk produkt indeholdende en kombination af amantadin og selegilin, fremgangsmåde til fremstilling af produktet og anvendelse af amantadin og selegilin til fremstilling af produktet | |
| MX2023000798A (es) | Peptidos funcionalizados como agentes antivirales. | |
| JP2003509349A5 (https=) | ||
| JP2009102342A5 (https=) | ||
| MX2023005983A (es) | Nuevos agentes antivirales derivados de la espiropirrolidina. | |
| MX2023001756A (es) | Peptidos funcionalizados como agentes antivirales. | |
| JP2009504748A5 (https=) | ||
| RU2010107843A (ru) | Бупропиона гидробромид и его терапевтические применения | |
| WO2009082819A8 (en) | Novel lupane derivatives | |
| US20220340650A1 (en) | Combination therapy with cgrp antagonists | |
| JP2013528600A5 (https=) | ||
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| RU2015107877A (ru) | Способы лечения болезни альцгеймера и фармацевтические композиции | |
| AR061584A1 (es) | Uso de 2-aminotetralinas sustituidas para la fabricacion de un medicamento para la prevencion, alivio y/o tratamiento de diversos tipos de dolor | |
| WO2004052847A3 (en) | Tricyclic steroid hormone nuclear receptor modulators | |
| MX2010007374A (es) | Nuevos derivados de c-21-ceto lupano, preparacion y uso de los mismos. | |
| WO2005030753A3 (en) | Therapeutic agents useful for treating pain | |
| WO2008092072A3 (en) | Modulators of the metabotropic glutamate receptor subtype 5 and uses thereof | |
| AU2017261303A1 (en) | Ophthalmic compositions | |
| JP2019515052A5 (https=) | ||
| UA81640C2 (ru) | Противомикобактериальные соединения, способ их получения, фармацевтическая композиция на их основе | |
| JP2011006409A5 (https=) | ||
| JP2019531286A5 (https=) | ||
| JP2012504584A5 (https=) | ||
| JP2018525447A5 (https=) |